Skip to content Skip to footer

The European Cannabis Report: 6th Edition Lead Sponsor Foreword from Mario Eimuth, Founder ADREXPharma GmbH

The European Cannabis Report: 6th Edition Lead Sponsor Foreword from Mario Eimuth, Founder ADREXPharma GmbH
Share this story

 

mario eimuth

These are impressive numbers and they mirror the latest jurisdiction regarding CBD from the Court of Justice of the European Union (CJEU) that confidence and professionality are at the heart of this growth. European countries are experiencing transformation in the regulations controlling the marketing of cannabis products.

At ADREXpharma® we strive to lead the way in product innovation and development in order to respond and participate fully in any potential market growth.

European cannabis market growth

ADREXpharma® is the first independent German pharmaceutical company specialising in the development and distribution of medicinal cannabis and also providing a gateway into the European market. Our product portfolio consists not only of a wide range of cannabis flowers and extracts but also compounding products like dronabinol and pharmaceutical Cannabidiol (CBD) as well as innovative CBD-Cosmetic-Products. Due to our unique supply network, ADREXpharma® sets a new benchmark level by serving all of the approximate 19,000 pharmacies in Germany.

Our two collaborations with the German pharma companies, STADA and Neuraxpharm, for the GMP (good manufacturing practice) Full-Service and the distribution of Canadian and Israeli medical cannabis products has expanded our international footprint and has mirrored the tendency in the market for strategic collaborations within Europe and beyond.

We are proud to be one of the few German companies to hold all the necessary licences to operate in the German medical cannabis market. This will accelerate our growth potential even further over the next few years.

At ADREXpharma® we are committed to quality, authenticity and innovation, as well as to contributing to the growing body of evidence-based research regarding the benefits and efficacy of cannabis to validate new therapy options for patients. ADREXpharma® aims to provide the best possible treatment for medical cannabis patients – today and always.

Mario Eimuth
Founder ADREXpharma® GmbH

The European Cannabis Report: 6th Edition takes a deep dive on the current social, economic, regulatory and health trends. The report also includes sales forecasts of medical and adult-use cannabis in the US and Canada.

DOWNLOAD FOR FREE

Recent posts
June 2, 2022
Austria Sees Record Imports of Medical Cannabis in 2021
May 19, 2022
Who Are Europe’s Medical Cannabis Patients?
May 5, 2022
Europe’s Pilot Trials Are a Tentative Step Towards Legal Medical Cannabis
April 28, 2022
The First Sales of Legal Adult-Use Cannabis in Europe Are Due in 2022

Catch up on our newest articles that you might have missed

joss-woodhead-3wFRlwS91yk-unsplash
June 2, 2022
Austria Sees Record Imports of Medical Cannabis in 2021
Austria sees record imports of medical cannabis in 2021 while a case at the Supreme Court challenges prohibition. Austria is...
Untitled design (11)
May 19, 2022
Who Are Europe’s Medical Cannabis Patients?
The relatively close integration of medical cannabis into the European healthcare systems has contributed to a patient population and purchasing...
il-vagabiondo-Q7QCj-9-q3I-unsplash
May 5, 2022
Europe’s Pilot Trials Are a Tentative Step Towards Legal Medical Cannabis
Underlining the cautious approach Europe is taking to the liberalisation of medical cannabis are the pilot trial access schemes for...
vincent-ghilione-z54zUmYA9f8-unsplash
April 28, 2022
The First Sales of Legal Adult-Use Cannabis in Europe Are Due in 2022
Last week the first pilot project trial for the legalised sales of adult-use cannabis in Basel, Switzerland was approved by...